

Our Ref: 338/2022

September 2022

## Re: Your request made under the Freedom of Information Act 2000

Please can I request (under the FOIA 2000):

It would be really helpful if you could provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia] – 13 on Homecare Pathway
- Adalimumab [Humira] – 31 on Homecare Pathway
- Adalimumab Biosimilars – 801 via Homecare Pathway
- Apremilast [Otezla] – 3 on Homecare Pathway – also done through Outpatients, but due to Cost Centre unable to verify which are Rheumatology
- Baricitinib [Olumiant] – 7 on Homecare Pathway – also done through Outpatients, but due to Cost Centre unable to verify which are Rheumatology
- Certolizumab [Cimzia] – 24 on Homecare Pathway
- Etanercept [Enbrel] – 33 on Homecare Pathway
- Etanercept Biosimilars – 313 via Homecare Pathway
- Filgotinib [Jyseleca] – 2 on Homecare Pathway – also done through Outpatients, but due to Cost Centre unable to verify which are Rheumatology

Our Ref: 338/2022

September 2022

- Golimumab [Simponi] – 47 via Homecare Pathway
- Guselkumab [Tremfya] - 0
- Infliximab [Remicade] – Unable to verify actual numbers due to Cost Centre
- Infliximab Biosimilars – Unable to verify actual numbers due to Cost Centre
- Ixekizumab [Taltz] -12 via Homecare Pathway
- Risankizumab [Skyrizi] - 0
- Rituximab [MabThera] – Unable to verify actual numbers due to Cost Centre
- Rituximab Biosimilars – Unable to verify actual numbers due to Cost Centre
- Sarilumab [Kevzara] – 8 via Homecare Pathway
- Secukinumab [Cosentyx] – 57 via Homecare Pathway
- Tocilizumab [Ro Actemra] – 23 via Homecare Pathway
- Tofacitinib [Xeljanz] – 4 via Homecare Pathway
- Upadacitinib [Rinvoq] - 0
- Ustekinumab [Stelara] – 8 via Homecare Pathway



**Doncaster and Bassetlaw  
Teaching Hospitals**  
NHS Foundation Trust

Our Ref: 338/2022

September 2022